BACKGROUND: MAGE1 was originally isolated from human melanoma cells as a target antigen for autologous cytotoxic T lymphocytes. Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines. AIM OF THE STUDY: To determine if Mage-1 is expressed in pancreatic endocrine neoplasms (PENs) and PEN metastases. METHODS: We utilized immunolabeling analysis for Mage-1 on 49 primary PENs, 11 liver metastases, and 6 lymph node metastases. A semiquantitative labeling index (LI) of 0 (no expression), 1, 2 (moderate expression), and 3 (intense expression, correlating with internal control markers) was used to determine relative amounts of MAGE1 expression in these lesions. RESULTS: We have identified MAGE1 expression in a subset (42 of 49; 86%) of PENs. Normal pancreatic ducts, present in tissue adjacent to PENs, were utilized as a positive control for Mage-1 immunolabeling (index score 3); no other detectable labeling for Mage-1 was evident in normal pancreatic tissue. Primary PENs, with or without metastases (mean LI score 1.2 vs 1.0, respectively), did not demonstrate a significant difference in Mage-1 LI, although intratumoral heterogeneity was apparent in some, but not all, of these lesions. Lymph node metastases (mean score 2.0) demonstrated a significant increase in Mage-1 LI as compared to primary, non-metastatic lesions (p = 0.04984) and primary metastatic lesions (p = 0.02351). In contrast, six patients with a survival of less than one year demonstrated a low Mage-1 LI (mean score, 0.58). CONCLUSIONS: MAGE1 expression is present in a subset of primary PENs and in lymph node metastases, and may therefore serve as a useful marker and potential therapeutic target in PENs. Furthermore, the absence of Mage-1 expression in a subset of primary PENs may indicate a worsened prognosis.
BACKGROUND:MAGE1 was originally isolated from humanmelanoma cells as a target antigen for autologous cytotoxic T lymphocytes. Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines. AIM OF THE STUDY: To determine if Mage-1 is expressed in pancreatic endocrine neoplasms (PENs) and PEN metastases. METHODS: We utilized immunolabeling analysis for Mage-1 on 49 primary PENs, 11 liver metastases, and 6 lymph node metastases. A semiquantitative labeling index (LI) of 0 (no expression), 1, 2 (moderate expression), and 3 (intense expression, correlating with internal control markers) was used to determine relative amounts of MAGE1 expression in these lesions. RESULTS: We have identified MAGE1 expression in a subset (42 of 49; 86%) of PENs. Normal pancreatic ducts, present in tissue adjacent to PENs, were utilized as a positive control for Mage-1 immunolabeling (index score 3); no other detectable labeling for Mage-1 was evident in normal pancreatic tissue. Primary PENs, with or without metastases (mean LI score 1.2 vs 1.0, respectively), did not demonstrate a significant difference in Mage-1 LI, although intratumoral heterogeneity was apparent in some, but not all, of these lesions. Lymph node metastases (mean score 2.0) demonstrated a significant increase in Mage-1 LI as compared to primary, non-metastatic lesions (p = 0.04984) and primary metastatic lesions (p = 0.02351). In contrast, six patients with a survival of less than one year demonstrated a low Mage-1 LI (mean score, 0.58). CONCLUSIONS:MAGE1 expression is present in a subset of primary PENs and in lymph node metastases, and may therefore serve as a useful marker and potential therapeutic target in PENs. Furthermore, the absence of Mage-1 expression in a subset of primary PENs may indicate a worsened prognosis.
Authors: C Fischer; F Gudat; P Stulz; C Noppen; C Schaefer; P Zajac; M Trutmann; T Kocher; M Zuber; F Harder; M Heberer; G C Spagnoli Journal: Int J Cancer Date: 1997-06-11 Impact factor: 7.396
Authors: Martin Bolli; Thomas Kocher; Michel Adamina; Ulrich Guller; Peter Dalquen; Philippe Haas; Martina Mirlacher; Franco Gambazzi; Felix Harder; Michael Heberer; Guido Sauter; Giulio C Spagnoli Journal: Ann Surg Date: 2002-12 Impact factor: 12.969
Authors: P Jay; C Rougeulle; A Massacrier; A Moncla; M G Mattei; P Malzac; N Roëckel; S Taviaux; J L Lefranc; P Cau; P Berta; M Lalande; F Muscatelli Journal: Nat Genet Date: 1997-11 Impact factor: 38.330
Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon Journal: Science Date: 1991-12-13 Impact factor: 47.728
Authors: Sandra R Reynolds; Anne Zeleniuch-Jacquotte; Richard L Shapiro; Daniel F Roses; Matthew N Harris; Dean Johnston; Jean-Claude Bystryn Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon Journal: Int J Cancer Date: 1989-10-15 Impact factor: 7.396
Authors: C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon Journal: J Exp Med Date: 1992-11-01 Impact factor: 14.307
Authors: Michael G House; John L Cameron; Keith D Lillemoe; Richard D Schulick; Michael A Choti; Donna E Hansel; Ralph H Hruban; Anirban Maitra; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-01 Impact factor: 3.267